Psilocybin for clinical indications: A scoping review
Journal of Psychopharmacology August 13, 2024 Kim Madden, Breanne Flood, Darren Young Shing et al. 13 citations
A systematic scoping review of clinical indications for psilocybin identified 193 published and 80 ongoing studies. Most studies had small sample sizes, with a median of 22 participants and 18 who had taken psilocybin. Only 12% were randomized controlled trials, while 37% were systematic reviews. The most common indication studied was depression (28%), followed by substance use (14%), mental health in life-threatening illness (9%), headaches (6%), depression and anxiety (6%), obsessive-compulsive disorder (3%), and anxiety disorders (3%). Thirty-eight percent of studies reported at least one potential conflict of interest. The authors conclude there is a need for high-quality randomized trials and to expand consideration to other promising indications, such as chronic pain.